CTLA4 and non-small cell lung carcinoma: Ipilimumab (anti-CTLA-4), bevacizumab (anti-VEGF), and anti programmed death (anti-PD-1) or anti-PD ligand 1 (Anti-PD-L1) are examples of passive immunotherapy that could be useful in NSCLC[23-26].